Supplementary Table 1. Treatment details of all patients.
| Number | Age/sex | Primary site and type | AR | HER2 | First line | Second line | Third line | Outcome |
|---|---|---|---|---|---|---|---|---|
| 1 | 46/M | ACC, Parotid | - | - | Obs | NA | NA | Alive |
| 2 | 54/F | ACC, Parotid | Neg | Neg | P C Cycle1 | NA | NA | Death |
| 3 | 68/F | ACC, Parotid | Neg | Neg | SA Gem | OMCT | NA | Lost to follow-up |
| 4 | 66/F | ACC, Parotid | Neg | Neg | BSC | NA | NA | Death |
| 5 | 29/F | ACC, Parotid | - | - | CAB | NA | NA | Death |
| 6 | 51/F | ACC, Parotid | Neg | - | Obs | P C f/b OMCT Maint | NA | Alive |
| 7 | 54/M | ACC, SMG | Neg | Neg | Pall RT | NA | NA | Death |
| 8 | 35/F | ACC, Sublingual | Neg | Neg | P C | P C Rechallenge | Lenvatinib | Alive |
| 9 | 40/M | ACC, Minor salivary gland | Neg | Neg | P C | P C | NA | Alive |
| 10 | 40/M | ACC, Parotid | Neg | Neg | CAP | P C | Lenvatinib | Alive |
| 11 | 28/M | ACC, Minor salivary gland | Neg | Neg | Sorafenib | Enzalutam-ide | P C | Alive |
| 12 | 60/M | SDC, SMG | Pos | Pos | Pall RT | NA | NA | Death |
| 13 | 35/F | SDC, Parotid | - | Pos | Pall RT | NA | NA | Lost to follow-up |
| 14 | 72/M | SDC, Parotid | Pos | Neg | Pall RT | NA | NA | Death |
| 15 | 58/M | SDC, Parotid | Pos | Neg | P C | CAB | NA | Death |
| 16 | 65/M | SDC, Parotid | Neg | Pos | P C Trastu | NA | NA | Death |
| 17 | 42/M | SDC, Parotid | Pos | Pos | P C | NA | NA | Alive |
| 18 | 82/M | SDC, Parotid | Pos | Neg | CAB | NA | NA | Alive |
| 19 | 58/M | SDC, Parotid | Pos | Neg | BSC | NA | NA | Death |
| 20 | 44/M | SDC, Parotid | Pos | Pos | Bicalutamide | NA | NA | Death |
| 21 | 62/M | SDC, Parotid | Pos | Pos | P C Trastu | CAB | NA | Alive |
| 22 | 52/M | SDC, Parotid | Pos | Neg | CAB | P C | NA | Lost to follow-up |
| 23 | 61/M | MEC, Parotid | Pos | Pos | P C | P C Trastu + Leuprolide | NA | Death |
| 24 | 46/M | MEC, Parotid | Neg | Neg | CAP | NA | NA | Death |
| 25 | 35/M | MEC, SMG | - | - | Obs | NA | NA | Alive |
| 26 | 67/M | MEC, Parotid | Neg | Neg | P C | NA | NA | Death |
| 27 | 25/M | MEC, Parotid | Neg | Neg | Doce Cis | Pall RT | NA | Death |
| 28 | 81/M | MEC, SMG | Neg | - | LD Nivo + OMCT | NA | NA | Death |
| 29 | 58/M | MEC, SMG | Neg | Neg | CAP | Paclitaxel | NA | Lost to follow-up |
| 30 | 38/F | MASC, Parotid | NTRK 1 Pos | Obs | NA | NA | Alive | |
ACC: adenoid cystic carcinoma, AR: androgen receptor, BSC: best supportive care, CAB: combined androgen blockade, CAP: cyclophosphamide, adriamycin, cisplatin, Doce cis: docetaxel plus cisplatin, F: female, HER2: human epidermal growth factor receptor 2, LD Nivo: low dose Nivolumab, M: male, MASC: mammary analogue secretory carcinoma, MEC: muco-epidermoid carcinoma, NA: not applicable, Neg: negative, NTRK: neurotrophic tyrosine receptor kinase, Obs: observation, OMCT: oral metronomic chemotherapy, P C: paclitaxel plus carboplatin, Pall: palliative, Pos: positive, RT: radiotherapy, Trastu: trastuzumab, SDC: salivary duct carcinoma, SMG: submandibular gland.